In this study, we observed that PAPPA2 mutation was mostly enriched in patients with NSCLC and SKCM while strongly differenced in patients with objective response to ICIs versus without in the NSCLC and SKCM sets. This evidence concerns the gene PAPPA2 and non-small cell lung carcinoma.